577 related articles for article (PubMed ID: 34627340)
1. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
Trials; 2014 Jan; 15():14. PubMed ID: 24405833
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
5. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial.
Acharya NR; Ebert CD; Kelly NK; Porco TC; Ramanan AV; Arnold BF;
Trials; 2020 Oct; 21(1):887. PubMed ID: 33109240
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
[TBL] [Abstract][Full Text] [Related]
7. Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany.
Heiligenhaus A; Klotsche J; Niewerth M; Horneff G; Ganser G; Haas JP; Minden K
Arthritis Res Ther; 2020 Apr; 22(1):81. PubMed ID: 32293540
[TBL] [Abstract][Full Text] [Related]
8. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
9. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
Quartier P; Baptiste A; Despert V; Allain-Launay E; Koné-Paut I; Belot A; Kodjikian L; Monnet D; Weber M; Elie C; Bodaghi B;
Ann Rheum Dis; 2018 Jul; 77(7):1003-1011. PubMed ID: 29275333
[TBL] [Abstract][Full Text] [Related]
10. Juvenile idiopathic arthritis-associated uveitis.
Sen ES; Ramanan AV
Clin Immunol; 2020 Feb; 211():108322. PubMed ID: 31830532
[TBL] [Abstract][Full Text] [Related]
11. Screening for juvenile idiopathic arthritis associated uveitis with laser flare photometry in the pediatric rheumatology office: a prospective observational study.
Ede K; Shishov M; Wershba E; Goswami N; Gorry S; Joseph M; Mirea L; O'Neil J
Pediatr Rheumatol Online J; 2024 Jan; 22(1):22. PubMed ID: 38279120
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
Fautrel B; Zhu B; Taylor PC; van de Laar M; Emery P; De Leonardis F; Kannowski CL; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371431
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).
Ramanan AV; Dick AD; Jones AP; Guly C; Hardwick B; Hickey H; Lee R; McKay A; Beresford MW;
BMC Rheumatol; 2018; 2():4. PubMed ID: 30886955
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis.
Storwick JA; Brett AC; Buhler K; Chin A; Schmeling H; Johnson NA; Fritzler MJ; Choi MY
Autoimmun Rev; 2022 Jun; 21(6):103086. PubMed ID: 35398272
[TBL] [Abstract][Full Text] [Related]
18. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
20. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
Thomas J; Kuthyar S; Shantha JG; Angeles-Han ST; Yeh S
Ann Eye Sci; 2021 Jun; 6():. PubMed ID: 34131629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
